T. Rowe Price Associates
MIRM icon

T. Rowe Price Associates’s Mirum Pharmaceuticals MIRM Stock Holding History

T. Rowe Price Associates’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311M Buy
2,655,607
+938,186
+55% +$94.2M 0.03% 385
2026
Q1 		$159M Buy
1,717,421
+297,046
+21% +$27.9M 0.02% 511
2025
Q4 		$112M Buy
1,420,375
+137,087
+11% +$9.84M 0.01% 604
2025
Q3 		$94.1M Sell
1,283,288
-133,927
-9% -$8.51M 0.01% 636
2025
Q2 		$72.1M Buy
1,417,215
+2,078
+0.1% +$92.5K 0.01% 643
2025
Q1 		$63.8M Sell
1,415,137
-7,592
-0.5% -$358K 0.01% 647
2024
Q4 		$58.8M Buy
1,422,729
+138,623
+11% +$5.78M 0.01% 706
2024
Q3 		$50.1M Buy
1,284,106
+84,886
+7% +$3.39M 0.01% 754
2024
Q2 		$41M Sell
1,199,220
-398,286
-25% -$10.4M ﹤0.01% 782
2024
Q1 		$40.1M Buy
1,597,506
+432,824
+37% +$11.9M ﹤0.01% 779
2023
Q4 		$34.4M Buy
1,164,682
+1,132,723
+3,544% +$34.3M ﹤0.01% 804
2023
Q3 		$1.01M Sell
31,959
-67,722
-68% -$1.85M ﹤0.01% 1795
2023
Q2 		$2.58M Buy
99,681
+87,753
+736% +$2.33M ﹤0.01% 1392
2023
Q1 		$287K Sell
11,928
-4,903
-29% -$112K ﹤0.01% 2366
2022
Q4 		$328K Buy
16,831
+4,800
+40% +$94.9K ﹤0.01% 2339
2022
Q3 		$253K Buy
+12,031
New +$290K ﹤0.01% 2456

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates's MIRM Position: Q2 2026 in Review

T. Rowe Price Associates increased its Mirum Pharmaceuticals (MIRM) stake by 55% in Q2 2026, buying an estimated $94.2M and bringing the position to 2,655,607 shares worth $311M. The position accounts for 0.03% of the portfolio, ranked #385.

T. Rowe Price Associates first reported a position in MIRM in Q3 2022 and has held it in 16 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • T. Rowe Price Associates held 2,655,607 shares of Mirum Pharmaceuticals worth $311M as of Q2 2026.
  • T. Rowe Price Associates bought 938,186 Mirum Pharmaceuticals shares in Q2 2026, an estimated $94.2M.
  • Mirum Pharmaceuticals made up 0.03% of T. Rowe Price Associates's portfolio in Q2 2026, its #385 holding.
  • T. Rowe Price Associates first reported a position in Mirum Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.